GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Graham Number

Biocept (Biocept) Graham Number : $N/A (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biocept Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-04-26), the stock price of Biocept is $0.0001. Biocept's graham number for the quarter that ended in Jun. 2023 was $N/A. Therefore, Biocept's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Biocept's Graham Number or its related term are showing as below:

During the past 12 years, the highest Price to Graham Number ratio of Biocept was 1.41. The lowest was 1.41. And the median was 1.41.

BIOCQ's Price-to-Graham-Number is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.82
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Biocept Graham Number Historical Data

The historical data trend for Biocept's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Graham Number Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biocept's Graham Number

For the Diagnostics & Research subindustry, Biocept's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's Price-to-Graham-Number Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Biocept's Price-to-Graham-Number falls into.



Biocept Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Biocept's Graham Number for the fiscal year that ended in Dec. 2022 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*15.571*-56.7)
=N/A

Biocept's Graham Number for the quarter that ended in Jun. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*0.12*-53.256)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocept  (OTCPK:BIOCQ) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Biocept's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jun. 2023 )
=0.0001/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Biocept Graham Number Related Terms

Thank you for viewing the detailed overview of Biocept's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121